A company called Esperion Therapeutics, which makes medicine, had a deal with another company from Japan, called Daiichi Sankyo. They decided to change their deal and agreed to pay each other $125 million more. Also, they will stop a legal fight in court that was happening between them. Because of this news, the price of Esperion Therapeutics' shares went down today. Read from source...

1. The title is misleading and sensationalized. It should be something like "Esperion Therapeutics Announces $125 Million Amendment with Daiichi Sankyo Europe" or "Legal Dispute Resolved Between Esperion Therapeutics and Daiichi Sankyo". The current title implies that the company is in trouble, which may scare away potential investors.
2. The article does not provide any context for the legal action pending in the US District Court for the Southern District of New York. Why was it filed? What were the main issues involved? How long has it been going on? This information would help readers understand the background and significance of the settlement.
3. The article mentions that Esperion Therapeutics shares are trading lower, but does not explain why or by how much. This is important for readers to know if they are interested in investing in the company or following its performance.
4. The last sentence of the article is overly positive and unrealistic. It implies that both companies are solely focused on delivering life-saving drug therapies, which may not be true. There may be other factors affecting their decisions, such as profitability, market share, competition, etc. The author should acknowledge these complexities and present a more balanced view.
5. The article does not provide any sources or references for the information it presents. This makes it difficult to verify the accuracy and reliability of the claims made by the author. A good practice would be to cite reputable news outlets, academic journals, industry reports, or official statements from the companies involved.

Negative
Explanation: The article discusses how Esperion Therapeutics shares are diving today due to a $125 million amendment to the collaboration with Daiichi Sankyo Co. This implies that the market is not reacting favorably to this news and the share prices are falling, indicating a negative sentiment.

Esperion Therapeutics is a biopharmaceutical company that focuses on developing and commercializing therapeutics for lipid management and cardiovascular disease. The company's lead product, ETC-1001, is an oral, once-daily, selective inhibitor of ATP-citrate lyase, a key enzyme involved in the production of cholesterol.